SION

Sionna Therapeutics, Inc. (SION) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Balance Sheet Liquidity

Very strong liquidity with a current ratio of 20.0x and cash ratio of 5.9x.

Low leverage with debt-to-equity of 0.03x and debt-to-assets of 2.8%.

Net debt remains modest at 0.59x EBITDA.

Profitability Cash Flow

Trailing margins and returns remain deeply negative, with ROA at -34.4%, ROE at -32.9%, and ROIC at -40.0%.

Operating cash flow and free cash flow are both negative, with FCF yield at -33.6% and OCF yield at -30.0%.

Cash conversion is weak despite a high income quality ratio, reflecting ongoing losses rather than durable earnings.

Valuation Downside Protection

The stock screens as inexpensive on asset-based measures, with price-to-book at 1.10x and net current asset value of $198.7M.

Negative earnings and cash flow make earnings-based valuation metrics less meaningful, limiting confidence in headline cheapness.

Graham net-net value of 4.29 suggests some asset-backed downside support.

Operational Efficiency

Asset turnover and operating margins are effectively zero, indicating limited operating efficiency in the current period.

Days payable outstanding is extremely high at 623.8 days, which may reflect stretched working-capital management.

Cash conversion cycle is deeply negative at -623.8 days, but this appears driven by payables rather than strong operating performance.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sionna Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →